Jim Tananbaum, Chief Executive Officer and Founder of Foresite Capital

Jim Tananbaum serves as the Chief Executive Officer and Founder of Foresite Capital. In 2011, Jim Tananbaum Foresite Capital founded Foresite Capital, a private equity healthcare firm that specializes in the identification of emerging leaders in the healthcare industry.

About Foresite Capital

The headquarters of Foresite Capital are in San Francisco. Furthermore, in New York, the Healthcare firm also has an additional office. Foresite Capital invests in the top most innovative healthcare companies. Also, the company offers growth capital to emerging healthcare providers in the private and public sectors. The investments are done on enterprises that have disruptive last-stage services as products. The company is valued at about 1.1 billion dollars in terms of assets. Intarcia is Foresite’s latest and largest investment. Intarcia is a type II diabetes implant that helps patients to control their diabetes and weight.

About Jim Tananbaum

Before establishing Foresite Capital, Jim was a co-founder of two healthcare investment practices and two biopharmaceutical companies. Jim Tananbaum has over 25years of experience in the healthcare sector where he has served at management positions at GelTex and Theravance Pharmaceuticals. In 1998, GelTex was acquired for 1.6 billion dollars, and its lead drug called Renzela had an excess revenue rate of 200 million dollars. He is also a founding partner at Sierra Ventures and Prospect Venture Partners II and III. Check out his About.me page

In 1998, Jim Tananbaum obtained an M. D and an M.B.A from Havard Business School. Jim also majored in Math and computer science/electrical engineering from Yale University. Jim holds an M.S. from the Massachusetts Institute of Technology. He has productive and long-term relationships with leading academicians and has been mentored by Rick Levin from Yale, George Whitesides from Harvard and Roy Vagelos from Theravance. Jim continues to collaborate with these leading academicians and entrepreneurs in a bid to develop new great insights in the healthcare industry.

Jim Tananbaum has appeared on the Midas List for three years straight. This list features the top hundred investors. Jim has undertaken various major investments in the health sector including two diabetes treatment unicorns known as Juno Therapeutics and Intarcia Therapeutics.

See more: https://ideamensch.com/jim-tananbaum/

Leave a Reply

Your email address will not be published. Required fields are marked *